AbCellera
Business Services · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2215 Yukon St, Vancouver, British Columb...Phone Number
(604) 559-9005Website
www.abcellera.comRevenue
$79.2 MillionStock Symbol
ABCLIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
4
4
1
1
2
About AbCellera
AbCellera is a biotechnology company based in Vancouver, Canada, specializing in antibody discovery and development. Their proprietary technology platform leverages single-cell screening, machine learning, and high-throughput genomics to identify and develop therapeutic antibodies. AbCellera collaborates with pharmaceutical and biotechnology companies to accelerate the development of antibody-based medicines across various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases.Explore more
AbCellera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AbCellera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if AbCellera is spiking on competitors!
Earning: See what the market has to say on AbCellera recently announced quarterly report
Check if AbCellera has recently received funding, and reach out quickly before it becomes old news!
AbCellera, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if AbCellera had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AbCellera
Funding: Get notified immidiatlly once AbCellera has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when AbCellera launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to AbCellera
Compare insights from companies similar to AbCellera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AbCellera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AbCellera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AbCellera.
AbCellera financials insights
Gather financial insights about AbCellera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$10M
2020
Series B
$105M
Stock Offering
$483M
2021
Stock Offering
$288.5M
AbCellera Tech Stack
A closer look at the technologies used by AbCellera
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Engineering, Research & Development, Contingent Workforce, Sales, Business Development, Outsourcing, Search, Bioengineering, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, HR Operations, Manufacturing Operations, Operations, Organizational Development
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
AbCellera has announced plans to complete Phase I development of ABCL575, its anti-OX40 ligand antibody, and will not allocate additional capital beyond Phase I, while remaining open to potential partnering opportunities given the molecule's expected long half-life and suitability for every six-month dosing.
Product Development, Pharmaceuticals
Project
AbCellera has confirmed that ABCL635 demonstrated a pharmacokinetic profile consistent with a once-monthly subcutaneous injection target product profile in Phase I, with an observed half-life of approximately 25 days supporting the planned monthly dosing regimen.
Research & Development, Pharmaceuticals
Project
Pharmaceuticals
AbCellera News & Media
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration
AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks. On June 17, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. The deal is to discover and develop next-generation T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors. The companies said the partnership includes $56 million […]Jazz and AbCellera sign deal for T-cell engagers in solid tumours
AbCellera will conduct discovery and early-stage research activities on two initial programmes.Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding AbCellera
Sign Up For FreeTo access detailed company insights
AbCellera is a biotechnology company based in Vancouver, Canada, specializing in antibody discovery and development. Their proprietary technology platform leverages single-cell screening, machine learning, and high-throughput genomics to identify and develop therapeutic antibodies. AbCellera collaborates with pharmaceutical and biotechnology compan... Read More
